FYBFormycon AG
19.30EUR+3.43%Mkt Cap: 370.75M $P/E:

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular …

HeadlineSourceTime
This week
finanzen.ch
finanzen.ch
finanzen.net
Older
4investors.de
Formycon AG (WBO:FYB) (Q2 2026) Earnings Call Highlights: Revenue Nearly Triples on Strong ...

Formycon AG (WBO:FYB) reports a significant revenue surge and improved EBITDA, driven by commercial momentum and strategic partnerships.

GuruFocus.com
MarketScreener Deutschland
finanzen.net
4investors.de
MarketScreener Deutschland
BBondGuide
Wallstreet Online
boerse.de
finanzen.ch
finanzen.ch
Wallstreet Online
finanzen.ch
FinanzNachrichten.de
FinanzNachrichten.de
boerse.de
finanzen.ch
finanzen.ch
FinanzNachrichten.de
TradingView
boerse.de
Börse Express
Finanzen.net
GoingPublic.de
Simply Wall St.
GuruFocus.com
European Growth Leaders With High Insider Ownership

As European markets navigate a complex landscape of stalled geopolitical negotiations and fluctuating oil prices, the pan-European STOXX Europe 600 Index has remained largely stable with slight positive momentum in corporate earnings. In this environment, stocks with high insider ownership can be particularly attractive to investors seeking growth opportunities, as they often indicate strong alignment between company leadership and shareholders' interests.

Simply Wall St.
Downgrade: Here's How Analysts See Formycon AG (ETR:FYB) Performing In The Near Term

The analysts covering Formycon AG ( ETR:FYB ) delivered a dose of negativity to shareholders today, by making a...

Simply Wall St.
Formycon AG (XTER:FYB) Full Year 2025 Earnings Call Highlights: Transformational Year with ...

Despite revenue setbacks, Formycon AG (XTER:FYB) exceeded EBITDA expectations and set a positive outlook for 2026 with strategic initiatives and geographic diversification.

GuruFocus.com
February 2026's European Stocks Possibly Priced Below Estimated Value

As European markets continue to show resilience, with the pan-European STOXX Europe 600 Index reaching new highs and optimism about the eurozone economy bolstering investor sentiment, opportunities may arise for investors seeking stocks potentially priced below their estimated value. In this context, identifying undervalued stocks involves looking for companies that demonstrate strong fundamentals yet have not fully reflected these in their current market valuations amidst ongoing market...

Simply Wall St.
European Insider-Owned Growth Stocks To Watch In January 2026

As European markets face renewed trade and geopolitical uncertainty, with major indexes like the STOXX Europe 600 Index ending lower, investors are increasingly turning their attention to growth companies with high insider ownership. In such a volatile environment, stocks where insiders hold significant stakes can be particularly appealing due to the alignment of interests between company leaders and shareholders.

Simply Wall St.
European Growth Companies With High Insider Ownership In December 2025

As European markets show signs of steady economic growth and benefit from looser monetary policies, the pan-European STOXX Europe 600 Index has risen by 1.60%, reflecting a positive sentiment across major stock indexes. This environment highlights the importance of identifying growth companies with high insider ownership, as such stocks may offer unique insights into potential market opportunities amid evolving economic conditions.

Simply Wall St.
Formycon and Zydus sign exclusive agreement for FYB206 supply

On market launch of the product, Formycon will receive a mid–double-digit-share of gross profits in the region.

Pharmaceutical Technology